The semaglutide EPAR and what it actually tells UK patients

You found the EPAR, here's what you're actually looking at

Picture yourself deep in a research session: you've read the NHS medicines page, you've skimmed a couple of journal papers, and now you've landed on a dense document on the EMA's website with hundreds of pages of pharmacokinetic data. That's the European Public Assessment Report, and it's the EMA's full scientific justification for its centralised marketing authorisation. It was written for regulators and specialists, which explains why it reads the way it does.

A common misconception worth clearing up gently: many people assume that because the UK left the EU, the EPAR no longer applies at all to medicines used here. The reality is more nuanced. The EPAR is not a UK document, and UK prescriptions are not issued under it. But the underlying clinical evidence it draws on (the STEP trial programme, the pharmacology data, the safety analyses) was submitted to both the EMA and the MHRA as part of separate but largely parallel reviews. The clinical conclusions in the EPAR and the MHRA's own assessment are therefore closely aligned, even if the legal instruments are distinct.

For UK readers, the more directly relevant documents are the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet published on the Electronic Medicines Compendium, which reflect the MHRA-authorised UK licence. The EMA's EPAR remains useful as a transparent scientific record, particularly for clinicians wanting granular detail, but it is not the authority UK pharmacies or prescribers cite.

What the clinical evidence the EPAR draws on actually showed

The trial data at the heart of semaglutide's assessment (both for the EMA and MHRA) comes primarily from the STEP programme. STEP 1, published in the New England Journal of Medicine, followed 1,961 adults with obesity or overweight plus a weight-related condition over 68 weeks. Participants using semaglutide 2.4 mg alongside lifestyle changes lost around 15% of their body weight on average, compared with roughly 2.4% in the placebo group.

Those figures fed directly into both the EMA's and MHRA's decisions to authorise Wegovy for weight management. NICE subsequently appraised the evidence for NHS England use, and its guidance (TA875, published in March 2023) recommended semaglutide within specialist weight management services for a maximum of two years, for adults with a BMI of 35 or above and at least one weight-related condition. Lower BMI thresholds apply for some ethnic backgrounds. If you want to understand the full clinical picture for Wegovy before starting a consultation, the semaglutide overview on our site sets out the mechanism, the dosing schedule and what to expect.

More recent evidence has since expanded the picture. A higher 7.2 mg maintenance dose was approved by the MHRA in early 2026, with trial data reporting around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide results seen in head-to-head trials. The EPAR predates these newer approvals, which is a reminder that the document is a point-in-time record, not a live reference.

UK authorisations that the EPAR does not cover

Semaglutide's story in the UK has moved quickly. The MHRA has granted it authorisations that go beyond weight management, and these post-date or sit outside the original EMA centralised review that produced the weight-management EPAR. From 3 July 2026, a conditional approval covers the use of Wegovy in adults with MASH, a form of fatty liver disease involving moderate-to-advanced fibrosis. A separate authorisation covers reduction of major cardiovascular event risk in adults with established cardiovascular disease and obesity or overweight. Neither of these indications is what Wegovy is prescribed for at nume, where the focus is weight management, but they illustrate how the evidence base has grown.

The MHRA's Drug Safety Update channel is where UK-specific safety communications appear, including the January 2026 update on pancreatitis risk across GLP-1 medicines. These updates are binding on UK prescribers and pharmacies in a way that EMA communications are not. If you are managing a specific health condition alongside weight loss and want to understand how semaglutide fits, that is exactly the kind of question a prescriber should answer in a consultation. You can explore how that process works at nume if you'd like a clearer sense of what to expect before you start.

A brief note on Ozempic: it also contains semaglutide but holds a separate MHRA licence for type 2 diabetes management. Its EPAR likewise covers that indication. The two products are not interchangeable for weight loss, and Ozempic is not licensed or prescribed as a weight-loss medicine in the UK. People researching semaglutide for weight management should focus on Wegovy's specific authorisation rather than the diabetes indication. Details on the licensed starting dose for Wegovy and on dose progression are covered separately on our site, as are the specifics of moving to semaglutide 3 and what patients can expect when reaching the semaglutide 5 stage of the schedule.

Reading the EPAR alongside UK guidance, a practical note

If you do want to read the EMA's assessment, treat it as scientific background rather than a practical guide. The clinical pharmacology sections explain how semaglutide slows gastric emptying, increases satiety signalling and reduces energy intake, the mechanism that underlies what patients experience as a quieter appetite and smaller portions feeling satisfying. That context is genuinely useful.

For anything practical (dosing, storage, missed doses, interactions, what to do if a side effect worries you) the UK Patient Information Leaflet is the right document, and your prescriber or pharmacist is the right person to ask. The answers to common questions on our site cover a number of these areas, and our clinical team reviews every consultation personally. If you've been doing your research and feel ready to talk it through, a consultation is the natural next step. Our prescribers are available seven days a week for aftercare questions once you're on treatment. For background on how Wegovy fits into the broader range of weight-loss options, the treatment overview is worth a read.